Re-Vana is developing photocrosslinked technologies for delivery of a wide range of therapeutics that may dramatically extend the time between intravitreal, topical or other injectable routes of administrations to the eye. In addition, we can reduce or potentially eliminate the need for topical drug delivery. Our technologies may lead to a new generation of drugs that will only require 1-2 intravitreal or anterior segment administrations per year. The Re-Vana platforms may also be used with many drugs that have recently become generics or biosimilars that have demonstrated outstanding efficacy for short durations of time.